Impel Pharmaceuticals
1 known investors
Impel Pharmaceuticals develops therapies that combine its proprietary Precision Olfactory Delivery (POD) nasal drug-delivery technology with established therapeutics for diseases with high unmet medical needs. Its approved product Trudhesa is a dihydroergotamine mesylate nasal spray for the acute treatment of migraine in adults.